Shares Drop 12% as GeoVax Files 7.6M-Share Prospectus, Refocuses Pipeline
GOVX•GOVX•GOVX•GOVX•GeoVax Labs shares plunged 12% after the company filed a prospectus to resell up to 7.6 million shares and scrapped its COVID-19 vaccine candidate. The biotech will now concentrate on its GEO-MVA mpox/smallpox vaccine and Gedeptin cancer therapy, with cash runway secured through August 2026.
GeoVax shares fell 12% in one day after the company filed a prospectus for the resale of up to 7.6 million common shares tied to warrant exercises and a recent private placement, signaling increased free float and potential dilution.
The company discontinued development of its GEO-CM04S1 COVID-19 vaccine candidate, redirecting resources toward its lead GEO-MVA mpox/smallpox vaccine and Gedeptin head and neck cancer therapy, both positioned for expedited regulatory review.
GeoVax announced that its existing cash and equivalents, bolstered by a $2.7 million private placement, are expected to sustain operations through August 2026, with further proceeds possible upon exercise of outstanding warrants.
